Cargando…

Universal response in the RKO colon cancer cell line to distinct antimitotic therapies

Both classic and newer antimitotics commonly induce a prolonged mitotic arrest in cell culture. During arrest, cells predominantly undergo one of two fates: cell death by apoptosis, or mitotic slippage and survival. To refine this binary description, a quantitative understanding of these cell respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorz, Alexander, Botesteanu, Dana-Adriana, Levy, Doron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997697/
https://www.ncbi.nlm.nih.gov/pubmed/29895957
http://dx.doi.org/10.1038/s41598-018-27267-7
_version_ 1783331089712939008
author Lorz, Alexander
Botesteanu, Dana-Adriana
Levy, Doron
author_facet Lorz, Alexander
Botesteanu, Dana-Adriana
Levy, Doron
author_sort Lorz, Alexander
collection PubMed
description Both classic and newer antimitotics commonly induce a prolonged mitotic arrest in cell culture. During arrest, cells predominantly undergo one of two fates: cell death by apoptosis, or mitotic slippage and survival. To refine this binary description, a quantitative understanding of these cell responses is needed. Herein, we propose a quantitative description of the kinetics of colon carcinoma RKO cell fates in response to different antimitotics, using data from the single cell experiments of Gascoigne and Taylor (2008). The mathematical model is calibrated using the in vitro experiments of Gascoigne and Taylor (2008). We show that the time-dependent probability of cell death or slippage is universally identical for monastrol, nocodazole and two different doses of AZ138, but significantly different for taxol. Death and slippage responses across drugs can be characterized by Gamma distributions. We demonstrate numerically that these rates increase with prolonged mitotic arrest. Our model demonstrates that RKO cells exhibit a triphasic response - first, remain in mitosis, then undergo fast and slow transition, respectively- dependent on the length of mitotic arrest and irrespective of cell fate, drug type or dose.
format Online
Article
Text
id pubmed-5997697
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59976972018-06-21 Universal response in the RKO colon cancer cell line to distinct antimitotic therapies Lorz, Alexander Botesteanu, Dana-Adriana Levy, Doron Sci Rep Article Both classic and newer antimitotics commonly induce a prolonged mitotic arrest in cell culture. During arrest, cells predominantly undergo one of two fates: cell death by apoptosis, or mitotic slippage and survival. To refine this binary description, a quantitative understanding of these cell responses is needed. Herein, we propose a quantitative description of the kinetics of colon carcinoma RKO cell fates in response to different antimitotics, using data from the single cell experiments of Gascoigne and Taylor (2008). The mathematical model is calibrated using the in vitro experiments of Gascoigne and Taylor (2008). We show that the time-dependent probability of cell death or slippage is universally identical for monastrol, nocodazole and two different doses of AZ138, but significantly different for taxol. Death and slippage responses across drugs can be characterized by Gamma distributions. We demonstrate numerically that these rates increase with prolonged mitotic arrest. Our model demonstrates that RKO cells exhibit a triphasic response - first, remain in mitosis, then undergo fast and slow transition, respectively- dependent on the length of mitotic arrest and irrespective of cell fate, drug type or dose. Nature Publishing Group UK 2018-06-12 /pmc/articles/PMC5997697/ /pubmed/29895957 http://dx.doi.org/10.1038/s41598-018-27267-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lorz, Alexander
Botesteanu, Dana-Adriana
Levy, Doron
Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
title Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
title_full Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
title_fullStr Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
title_full_unstemmed Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
title_short Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
title_sort universal response in the rko colon cancer cell line to distinct antimitotic therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997697/
https://www.ncbi.nlm.nih.gov/pubmed/29895957
http://dx.doi.org/10.1038/s41598-018-27267-7
work_keys_str_mv AT lorzalexander universalresponseintherkocoloncancercelllinetodistinctantimitotictherapies
AT botesteanudanaadriana universalresponseintherkocoloncancercelllinetodistinctantimitotictherapies
AT levydoron universalresponseintherkocoloncancercelllinetodistinctantimitotictherapies